HomeIrelandSeroba Closes Fund IV, at €123M

Seroba Closes Fund IV, at €123M

Seroba, a Dublin, Ireland-based life sciences venture capital firm, closed its Fund IV, at €123M.

Alongside existing investors such as the European Investment Fund (EIF), the Ireland Strategic Investment Fund (ISIF), Enterprise Ireland (EI), Allied Irish Banks (AIB), the vehcile has received support from new investors including CDP Venture Capitala US corporate, and a number of family offices.

The fund will focus on innovative early-stage investments in life sciences companies, predominantly in Western Europe, and selectively in North America, with a primary focus on biotech. The vehicle will target up to 12 investments and has, to date, invested in 5 companies including Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics and Artica Therapeutics.

Since its launch Seroba has invested in thirty-two innovative life sciences companies, bringing to market twenty new medical devices and eight new therapeutics to date.

The investment team, distributed in Dublin, Paris and Milan, includes Partners Catello Somma, Jennifer McMahon, Daniel O’Mahony, Maud Lazare, Alan O’Connell, Andrew Duignan, Bruno Montanari, and Alan O’Connell.

VCWire

01/02/2024